Shares of Kinaxis Inc. (TSE:KXS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is C$205.00.
KXS has been the subject of several analyst reports. CIBC dropped their target price on Kinaxis from C$175.00 to C$170.00 in a research note on Friday, February 28th. ATB Capital lowered Kinaxis from an “outperform” rating to a “sector perform” rating and set a C$210.00 target price for the company. in a research note on Friday, May 9th. Royal Bank of Canada upped their target price on Kinaxis from C$210.00 to C$225.00 in a research note on Friday, May 9th. Stifel Nicolaus upped their price target on Kinaxis from C$195.00 to C$225.00 in a research note on Friday, May 9th. Finally, BMO Capital Markets upped their price target on Kinaxis from C$190.00 to C$225.00 in a research note on Friday, May 9th.
View Our Latest Report on Kinaxis
Insiders Place Their Bets
Kinaxis Stock Performance
Kinaxis stock opened at C$200.90 on Friday. The firm has a market capitalization of C$4.04 billion, a P/E ratio of 199.39, a PEG ratio of 3.60 and a beta of 0.78. The stock has a fifty day moving average price of C$187.32 and a 200 day moving average price of C$175.17. Kinaxis has a 52 week low of C$132.93 and a 52 week high of C$201.44. The company has a current ratio of 1.89, a quick ratio of 2.29 and a debt-to-equity ratio of 12.12.
Kinaxis Company Profile
Kinaxis Inc provides cloud-based subscription software for supply chain operations in the United States, Europe, Asia, and Canada. It offers RapidResponse, a cloud-based platform, which provides advanced planning, sales and operation planning, supply and demand planning, inventory management, and command and control center services.
See Also
- Five stocks we like better than Kinaxis
- What Investors Need to Know to Beat the Market
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Retail Stocks Investing, Explained
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Kinaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinaxis and related companies with MarketBeat.com's FREE daily email newsletter.